1. Home
  2. AVDL vs CGBD Comparison

AVDL vs CGBD Comparison

Compare AVDL & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • CGBD
  • Stock Information
  • Founded
  • AVDL 2015
  • CGBD 2012
  • Country
  • AVDL Ireland
  • CGBD United States
  • Employees
  • AVDL N/A
  • CGBD N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • CGBD Finance: Consumer Services
  • Sector
  • AVDL Health Care
  • CGBD Finance
  • Exchange
  • AVDL Nasdaq
  • CGBD Nasdaq
  • Market Cap
  • AVDL 861.4M
  • CGBD 1.0B
  • IPO Year
  • AVDL 1996
  • CGBD 2017
  • Fundamental
  • Price
  • AVDL $12.75
  • CGBD $13.93
  • Analyst Decision
  • AVDL Strong Buy
  • CGBD Hold
  • Analyst Count
  • AVDL 7
  • CGBD 4
  • Target Price
  • AVDL $19.00
  • CGBD $14.67
  • AVG Volume (30 Days)
  • AVDL 1.2M
  • CGBD 455.9K
  • Earning Date
  • AVDL 08-07-2025
  • CGBD 08-05-2025
  • Dividend Yield
  • AVDL N/A
  • CGBD 13.22%
  • EPS Growth
  • AVDL N/A
  • CGBD N/A
  • EPS
  • AVDL N/A
  • CGBD 1.15
  • Revenue
  • AVDL $221,075,000.00
  • CGBD $234,464,000.00
  • Revenue This Year
  • AVDL $56.78
  • CGBD $14.27
  • Revenue Next Year
  • AVDL $30.46
  • CGBD $5.97
  • P/E Ratio
  • AVDL N/A
  • CGBD $12.14
  • Revenue Growth
  • AVDL 132.35
  • CGBD N/A
  • 52 Week Low
  • AVDL $6.38
  • CGBD $13.12
  • 52 Week High
  • AVDL $17.30
  • CGBD $18.64
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 76.98
  • CGBD 51.18
  • Support Level
  • AVDL $10.79
  • CGBD $13.40
  • Resistance Level
  • AVDL $14.23
  • CGBD $13.85
  • Average True Range (ATR)
  • AVDL 0.59
  • CGBD 0.27
  • MACD
  • AVDL 0.14
  • CGBD -0.02
  • Stochastic Oscillator
  • AVDL 61.15
  • CGBD 57.61

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

Share on Social Networks: